| 13th week of 2010 patent applcation highlights part 33 |
| Patent application number | Title | Published |
|---|
| 20100080729 | Nickel-base alloy for gas turbine applications - A nickel-based alloy suitable for casting gas turbine components having a lower density and basic heat treating process while achieving improved strength is disclosed. Multiple embodiments of the alloy are disclosed capable of providing both directionally-solidified and equiaxed castings. Also disclosed is a method of making a cast and heat treated article utilizing the improved nickel-base alloy. | 2010-04-01 |
| 20100080730 | NICKEL-BASED SUPERALLLOY AND GAS TURBINE BLADE USING THE SAME - A Ni-based superalloy contains 13.1 to 16.0 percent by mass of Cr, 1.0 to 6.8 percent by mass of Co, 3.0 to 3.4 percent by mass of Al, 4.6 to 5.6 percent by mass of Ti, 2.0 to 4.4 percent by mass of Ta, 3.5 to 4.9 percent by mass of W, 0.1 to 0.9 percent by mass of Mo, 0.3 to 1.4 percent by mass of Nb, 0.05 to 0.20 percent by mass of C, and 0.01 to 0.03 percent by mass of B with the remainder being nickel and inevitable impurities. The superalloy excels in corrosion resistance, oxidation resistance, has high strength, and is used in parts of a gas turbine to be used at high temperature. The resulting gas turbine excels in durability. | 2010-04-01 |
| 20100080731 | Tin-Free Lead-Free Free-Cutting Magnesium Brass Alloy and Its Manufacturing Method - A tin-free lead-free free-cutting magnesium brass alloy comprises 56.0 to 64.0 wt % Cu, 1.05 to about 2.1 wt % Mg, 0.21 to 0.4 wt % P and other elements 0.002 to 0.9 wt % which comprise at least two elements selected from the group consisting of Al, Si, Sb, rare earth elements, Ti and B and the balance being Zn with unavoidable impurities, wherein a cutting percentage of the alloy is at least 80%. The process for producing such alloy is also proposed. The invented alloy is excellent in cuttability, castability, hot and cold workability, corrosion resistance, mechanical properties and weldability and particularly applicable in spare parts, forging and casting which need cutting and grinding process. The cost of necessary metal materials of the invented alloy is lower than lead-free free-cutting bismuth and antimony brass alloy and is equivalent to lead-contained brass alloy. | 2010-04-01 |
| 20100080732 | ANALYZER AND LIQUID CONTAINER - The present invention is to present an analyzer, comprising: a container holder for holding a liquid container, wherein the liquid container includes a container body having an opening at a top end and containing a liquid, and a cover for sealing the opening; a liquid aspirating device comprising a liquid aspirating tube for aspirating the liquid within the liquid container held by the container holder; and an opening device for opening the opening such that the liquid aspirating tube is able to be inserted into the liquid container, by conducting a first operation and a second operation, wherein the first operation releases a sealing state between the cover and the opening under a condition that the cover is covering the opening, and the second operation moves the cover to a position at which the opening is not being covered by the cover under a condition that the sealed state is being released. | 2010-04-01 |
| 20100080733 | NEEDLE ASSEMBLY FOR ASPIRATING AND DISPENSING FROM SEALED CONTAINERS - A needle assembly has at least one guide member supported by a first body for sliding movement between an extended position and a retracted position. A second body is attached to the guide member. A biasing member biases the guide member to the extended position. A liquid handling needle is coupled to the first body so sliding movement of the guide member toward the retracted position retracts the second body relative to the liquid handling needle. The second body is adapted to contact a sealed receptacle. The biasing member urges the guide member toward said extended position during insertion and during said removal of the needle from the receptacle whereby the second body remains in contact with the sealed receptacle as the guide member moves from its extended position to its retracted position during said insertion and from its retracted position to its extended position during said removal. | 2010-04-01 |
| 20100080734 | TIP PLATE FOR HIGH THROUGHPUT SCREENING APPLICATIONS - A pipette tip plate includes individual tips organized in ranks and files to match in pattern the array of wells in a standard well plate and held together by a web structure which permits individual tips to move into registration with individual pins of a robotic head. | 2010-04-01 |
| 20100080735 | PORTABLE HYDROGEN GENERATOR - Portable hydrogen generators are disclosed. In the various embodiments, the generator may include a chamber configured to endothermically decompose a material positioned within the chamber to generate hydrogen gas. A heater may be in thermal communication with the material to stimulate a release of the hydrogen gas. An electrical power source may be controllably coupled to the heater, so that electrical power delivered to the heater may be controlled in response to at least one detected property of the hydrogen gas. | 2010-04-01 |
| 20100080736 | METHOD OF PRODUCING ETHYL ACETATE - Methods and systems for the production of ethyl acetate are described herein. The methods and systems incorporate the novel use of a high shear device to promote dispersion and mixing of a carbonyl co-reactant (e.g. acetic acid, acetaldehyde) with ethanol. The high shear device may allow for lower reaction temperatures and pressures and may also reduce reaction time with existing catalysts. | 2010-04-01 |
| 20100080737 | EXHAUST GAS TREATMENT CATALYST AND EXHAUST GAS TREATMENT SYSTEM - Provided are an exhaust gas treatment catalyst capable of reducing ammonia leakage rate while keeping a sufficient NO | 2010-04-01 |
| 20100080738 | Method and System for Recycling Plastics - A system and method for recycling plastics. The system and method recover materials such as hydrocarbon gases, liquid hydrocarbon distillates, various polymers and/or monomers used to produce the original plastics. The system and method allow about one unit of input of energy input to the plastic recycler to be used to create one or more gaseous components and one or more liquid distillate components from a plastic that is being recycled. The one or more gaseous components and one or more liquid distillate components produce about one corresponding unit of useable output energy recovered from the recycling of the plastic. | 2010-04-01 |
| 20100080739 | Processes for the Isomerization of Normal Butane to Isobutane - In a normal butane isomerization process where the isomerization effluent ( | 2010-04-01 |
| 20100080740 | Processes for the Isomerization of Paraffins of 5 and 6 Carbon Atoms with Methylcyclopentane Recovery - In an isomerization process where the isomerization effluent ( | 2010-04-01 |
| 20100080741 | Apparatus for Mixing Regenerated and Carbonized Catalyst - An apparatus for mixing regenerated and carbonized catalyst involves obstructing upward flow of catalyst by one or more baffles between a catalyst inlet and a feed distributor. Each catalyst stream may be passed to opposite sides of a riser. Baffles obstruct upward flow to effect mixing of regenerated and carbonized catalyst to obtain a more uniform temperature and catalyst mixture before contacting the feed. | 2010-04-01 |
| 20100080742 | FABRICATING POLYMERS FOR OPTICAL DEVICES - High concentrations of dye may be prepared in combination with thermoplastic polymers and used in optical polymers as monomeric and dimeric molecular solutions. The method of preparing high concentration levels allows the control over the aggregation of dye molecules that is required to maintain effective nonlinear operation. The present invention is applicable to many systems and is essential to the successful production of working optical limiting devices and other optically transparent polymeric devices, as well as other photonic applications, such as nonlinear optics. | 2010-04-01 |
| 20100080743 | FLUIDIZED BED SPARGER - This invention relates to a sparger for injecting a gas-containing feed into a fluidized-bed, wherein the diffuser pipe is angled at least about 12.5° from vertical for gas velocities exiting the diffusers pipe at v less than 45.7 m/sec, and at least about 12.5° exp [0.00131 v] from vertical for gas velocities exiting the diffuser pipe at v equal to or greater than 45.7 m/sec. | 2010-04-01 |
| 20100080744 | PROCESS FOR ISOLATING METALLIC RUTHENIUM OR RUTHENIUM COMPOUNDS FROM RUTHENIUM-CONTAINING SOLIDS - The present invention relates to a process for mobilizing metallic ruthenium or ruthenium compounds from solids to form volatile ruthenium compounds by means of a gas stream containing a hydrogen halide and carbon monoxide, preferably hydrogen chloride and carbon monoxide, and for isolating the previously mobilized ruthenium compounds, preferably by deposition with cooling, e.g. in relatively cold zones, in particular on relatively cold surfaces, absorption in suitable solutions or adsorption on suitable support materials. | 2010-04-01 |
| 20100080745 | MULTI-STAGE PROCESS FOR PURIFYING CARBON DIOXIDE AND PRODUCING ACID - Carbon dioxide is purified by processes employing NOx-rich sulfuric acid that can be formed by removal of SO | 2010-04-01 |
| 20100080746 | METHOD FOR PRODUCING HIGHER SILANES - The invention relates to a method for producing dimeric and/or trimeric silicon compounds, in particular silicon halogen compounds. The claimed method is also suitable for producing corresponding germanium compounds. The invention also relates to a device for carrying out said method to the use of the produced silicon compounds. | 2010-04-01 |
| 20100080747 | PURIFYING CARBON DIOXIDE AND PRODUCING ACID - Carbon dioxide is purified by processes employing NOx-rich sulfuric acid that can be formed by removal of SO | 2010-04-01 |
| 20100080748 | CONTINUOUS METHOD AND APPARATUS OF PURIFYING CARBON NANOTUBES - Provided is a continuous method and apparatus of purifying carbon nanotubes. The continuous method and apparatus of purifying carbon nanotubes is characterized in a first purifying step for injecting a carbon nanotube liquid mixture containing an oxidizer into a purifying reactor under a sub-critical water or supercritical water condition at a pressure of 50 to 400 atm and a temperature of 100 to 600° C. to obtain a purified product, thereby removing amorphous carbon and producing the carbon nanotube product. | 2010-04-01 |
| 20100080749 | CARBON NANOTUBES, A METHOD OF PREPARING THE SAME AND AN ELEMENT USING THE SAME - Carbon nanotubes, a method for preparing the same and an element using the same are provided. The method for preparing carbon nanotubes includes synthesizing carbon nanotubes from carbon source using an arc-discharge method in the presence of catalysts and promoter, wherein the promoter contains an element capable of reducing the surface energy of carbon nanotubes. Carbon nanotubes with high purity and narrow diameter distribution can thus be prepared. | 2010-04-01 |
| 20100080750 | CADMIUM TELLURIDE PRODUCTION PROCESS - A method for producing cadmium telluride from elemental cadmium and elemental tellurium is disclosed. For example, the method disclosed can be used for producing multi-kilogram batches of cadmium telluride in a few hours. | 2010-04-01 |
| 20100080751 | Fine particles synthesis method and electronic-component manufacturing method - A method of synthesizing fine particles includes creating a subcritical or supercritical reaction environment by application of at least one of heat and pressure with a mixed medium of water and a solvent of lower critical temperature and lower critical pressure than water, so that the mixed medium comes into a supercritical state at a lower temperature and a lower pressure than those in a case of water alone; and leaving source materials under the created reaction environment as a reaction field for a predetermined time to produce fine particles. | 2010-04-01 |
| 20100080752 | Ultrafine particle of rutile-type titanium oxide - It is provided ultrafine particles of a rutile titanium oxide obtained by maintaining the pH of an aqueous solution of a titanium compound having a Ti concentration of from 0.07 to 5 mol/L in the range of −1 to 3 in the presence of a chelating agent. Such ultrafine particles of a rutile titanium oxide are useful for photocatalysts, high refractive index materials, ultraviolet absorbing materials and the like. | 2010-04-01 |
| 20100080753 | SELF-STARTED PROCESS FOR HYDROGEN PRODUCTION - A self-started process for hydrogen production, which comprises following steps: providing a gas mixture having a methanol/oxygen molar ratio less than or equal to 0.6; and conducting the gas mixture to flow through a Cu/ZnO-based catalyst bed. The Cu/ZnO-based catalyst contains copper, zinc oxide, aluminum oxide, manganese oxide and/or cerium oxide. The Cu/ZnO-based catalyst can initiate the POM reaction; then, the gas mixture will rise to a temperature of over 120° C., and the POM reaction generates a HRG at a reaction temperature of less than or equal to 180° C. The HRG contains less than 4 vol. % CO, and the POM reaction generates 1.8 moles hydrogen or more per 1 mole methanol consumed. | 2010-04-01 |
| 20100080754 | PROCESS FOR PRODUCING HYDROGEN WITH COMPLETE CAPTURE OF CO2 AND RECYCLING UNCONVERTED METHANE - The present invention concerns a process for producing hydrogen from a hydrocarbon feed and steam, comprising:
| 2010-04-01 |
| 20100080755 | COMPOSITION AND PROCESS FOR THE DISPLACEMENT OF HYDROGEN FROM WATER UNDER STANDARD TEMPERATURE AND PRESSURE CONDITIONS AND A HYDROGEN FUEL SYSTEM AND METHODS OF USING THE HYDROGEN FUEL SYSTEM - The present invention relates to the production of hydrogen gas. More particularly, the present invention relates to: (1) a composition and process for the displacement of hydrogen from water under standard temperature and pressure conditions; (2) a hydrogen fuel system; (3) a method for using the hydrogen fuel system in conjunction with a feedstock composition to produce hydrogen gas (e.g., onboard a vehicle); and (4) a method of using the hydrogen fuel system at a reduced cost (e.g., by providing a consumer rebate in exchange for the return of byproduct(s) collected after using the hydrogen fuel system). The composition (e.g., a feedstock composition) comprises finely divided metal powders (e.g., magnesium, or magnesium and aluminum) and can also contain a chloride salt (e.g., sodium chloride or potassium chloride). The process of the present invention comprises adding a composition of the present invention to water (either water that already contains chloride ions—such as seawater—or, alternatively, with compositions that contain a chloride salt, either fresh water or seawater), at standard temperature and pressure conditions, in order to create hydrogen gas from the displacement of hydrogen from the water The methods of the present invention also comprises contacting the feedstock composition of the present invention with water (either water that already contains chloride ions—such as seawater—or, alternatively, with compositions that contain a chloride salt, either fresh water or seawater), at standard temperature and pressure conditions, in order to create hydrogen gas from the displacement of hydrogen from the water. | 2010-04-01 |
| 20100080756 | METHODS FOR PROTECTING AND REGENERATING BONE MARROW USING CXCR3 AGONISTS AND ANTAGONISTS - CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases. | 2010-04-01 |
| 20100080757 | METHOD OF DETECTING ABNORMAL TISSUE - A method for detecting abnormal biological tissue includes administering a vasoactive agent and determining the rate of blood flow in a tissue of interest. | 2010-04-01 |
| 20100080758 | OPTICAL FLUORESCENT IMAGING - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence. | 2010-04-01 |
| 20100080759 | Method for Forming Nano-bubble - The present invention discloses a method for forming a nano-bubble. The forming method is different from the oil-water emulsion reaction in the prior art. The method comprises: taking an inorganic particle as a nucleus and performing a polymer coating process to coat at least one first polymer on the surface of the nucleus to form an organic/inorganic composite particle; then removing the nucleus of the organic/inorganic composite particle by way of the dissolution of a first solvent to form an impregnated nano-particle; performing a freeze-drying process to remove the first solvent to have the impregnated nano-particle form a hollow nano-particle; and finally dissolving the hollow nano-particle in a second solvent to form the nano-bubble. | 2010-04-01 |
| 20100080760 | Method, device, and system to control pH in pulmonary tissue of a subject - Methods, devices, and systems are provided which include an aerosol generator and a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject. The methods, devices, or systems which include the membrane may be configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue. | 2010-04-01 |
| 20100080761 | Extracts of Isochrysis sp. - The present invention relates to extracts of | 2010-04-01 |
| 20100080762 | SKIN CARE COMPOSITION - The present invention relates to an oral composition containing an optimal combination of nutritional ingredients at high concentrations and at optimal ratios in order to maintain and/or achieve health and/or beautiful look of the skin. | 2010-04-01 |
| 20100080763 | ACRYLIC-BASED COPOLYMER COMPOSITIONS FOR COSMETIC AND PERSONAL CARE - A composition for nails, skin and hair in the form of an aqueous emulsion or dispersion is provided. The composition comprises: (a) at least one copolymer comprising (i) about 10 to 85 weight percent of (meth)acrylate ester of C | 2010-04-01 |
| 20100080764 | Skin Treatment Systems - A basic facial and body treatment cosmetic formulation is a combination of a cationic emulsifying agent, an oil soluble liquid polymer and a naturally occurring lactate buffer system. The basic formulation is a starter system that can be specialized to skin moisturizers, skin lighteners, skin pigmenting agents, sunscreens, antioxidants, line reducing products, wrinkle reducing products, anti-cellulite products, pharmaceuticals and the like. | 2010-04-01 |
| 20100080765 | EYELASH MAKEUP COMPOSITION AND CONDITIONING KIT - A composition for making up or caring for keratin fibres, containing a continuous oily phase, at least one compound chosen from copolymers of an alkene and of vinyl acetate, and at least one polar wax. | 2010-04-01 |
| 20100080766 | EYELASH MAKEUP COMPOSITION AND PROCESS COMPRISING THE APPLICATION OF TWO COMPOSITIONS - Composition containing a continuous aqueous phase, at least one silicone surfactant and at least one crosslinked polyelectrolyte. Process for making up or caring for keratin fibres, by applying to keratin fibres the noted composition and a second composition different from the first. | 2010-04-01 |
| 20100080767 | COMPOUNDS - The present invention relates to compounds according to Formula 1; wherein R represents a hydrocarbon group, Z represents an oxyethylene group, B represents an alkyl chain comprising 1 to 5 carbon atoms, Y represents 0 or 1, X represents a number greater than zero, and their use as surfactants, and in particular as surfactants which act as foam promoting agents. | 2010-04-01 |
| 20100080768 | Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin - The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water. This composition serves several key applications: (1) it is a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents; (2) it acts as a method for utilizing other compositions in the treatment of inflammatory conditions of the skin including, but by no means limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitits, psoriasis, xerosis and atopia; (3) it is a treatment of inflammatory conditions of mucosae; (4) it relates to other compositions and methods for protecting and enhancing the barrier function of the skin. | 2010-04-01 |
| 20100080769 | Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies - Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen. | 2010-04-01 |
| 20100080770 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 2010-04-01 |
| 20100080771 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 2010-04-01 |
| 20100080772 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-04-01 |
| 20100080773 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 2010-04-01 |
| 20100080774 | LACTOCOCCUS PROMOTERS AND USES THEREOF - The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from | 2010-04-01 |
| 20100080775 | RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS) - The present invention relates to the field of gene therapy and the treatment of tumors. | 2010-04-01 |
| 20100080776 | METHOD OF ENHANCING AN IMMUNE RESPONSE - A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful in treating infectious diseases and cancer. | 2010-04-01 |
| 20100080777 | COMPOSITION CONTAINING AUTOLOGOUS MONONUCLEAR CELLS AND PIG COLLAGEN SCAFFOLD IN PASTE FORM AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR SURGICAL TREATMENT - Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments. | 2010-04-01 |
| 20100080778 | STEM CELL EXPANSION ENHANCING FACTOR AND METHOD OF USE - The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence having the activity of a peptide encoded by a Hoxb4 nucleotide sequence. Once delivered, the amino acid sequence is functionally active in the hematopoietic stem cell and enhances expansion thereof. The amino acid sequence may is a HOXB4 or HOXA4 protein. | 2010-04-01 |
| 20100080779 | Methods related to wound healing - The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination. | 2010-04-01 |
| 20100080780 | PLURIPOTENT AUTOLOGOUS STEM CELLS FROM ORAL MUCOSA AND METHODS OF USE - The present invention provides a new readily accessible source of adult somatic stem cells from the gastrointestinal tract in general and oral mucosa in particular, methods for isolating pluripotent stem cells from oral mucosa, cells derived therefrom and uses thereof. | 2010-04-01 |
| 20100080781 | Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion - This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. | 2010-04-01 |
| 20100080782 | Use of probiotic lactic acid bacteria for balancing the skin's immune system - The present invention pertains to the use of probiotics for the preparation of a carrier for balancing the skin's immune function. In particular, the present invention pertains to the use of probiotic micro-organisms for balancing the skin's immune function under stress conditions, such as a exposure to ultraviolet radiation, specifically for enhancing the skin's immune activity and reducing the tendency to develop allergic reactions under such conditions. | 2010-04-01 |
| 20100080783 | Microbial feed additive - A microbial feed additive comprising lactic acid bacteria, silicate such as bentonite, and a yeast culture. The animal feed additive of this invention results in more piglets born alive, reduced mortality in nursery pigs, improved growth performance in pregrower, growing and finishing pigs, improved utilization of dietary protein in pregrower and finishing pigs, and improved growth performance in stressed pigs. | 2010-04-01 |
| 20100080784 | METHODS FOR TREATING CACHEXIA AND LYMPHOPENIA - Disappearance of a cell population, designated CD4 | 2010-04-01 |
| 20100080785 | DRIED FORMULATIONS - The present invention provides novel formulations with improved bioavailability for substances such as ubiquinone, ubiquinol and omega-3 fatty acid. The present invention provides methods and compositions for drying formulations of such substances, wherein those dried formulations can readily be dissolved in water. The compositions and methods of the invention are of particular use in adding nutrients, such as vitamins and minerals, to food products such as beverages. | 2010-04-01 |
| 20100080786 | Phenyl or Pyridinyl Substituted Indazoles Derivatives - A compound of formula Ia: | 2010-04-01 |
| 20100080787 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN ENZYME WHICH IS INSOLUBLE IN AN AQUEOUS MEDIUM AS WELL AS ITS USES - The invention relates to a cosmetic or dermopharmaceutical composition, as well as these uses. | 2010-04-01 |
| 20100080788 | ALGINATE AND ALGINATE LYASE COMPOSITIONS AND METHODS OF USE - The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use. | 2010-04-01 |
| 20100080789 | THERAPEUTIC RIBONUCLEASES - The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease. | 2010-04-01 |
| 20100080790 | STERILIZATION USING HIGH-PRESSURE CARBON DIOXIDE - Disclosed are compositions and methods for the biocompatible sterilization of materials, in particular, of medical devices and implants. Sterilization is achieved by deactivation of microorganisms through treatment of the material with a mixture of at least one microbiocidal additive and a high-pressure or supercritical fluid, for example, high-pressure carbon dioxide or supercritical carbon dioxide. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2010-04-01 |
| 20100080791 | Composition and Method For Treating Tissue Defects - The present invention provides a composition and method for treating tissue defects. The composition includes thrombin and fibrinogen, or sodium alginate and calcium chloride, and also a surfactant, and non-resorbable polymer microparticles dispersed within the composition. | 2010-04-01 |
| 20100080792 | Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen - The present invention is a method for identifying MHC class II-dependent disease-associated antigens. The instant method involves expressing a library of disease-derived proteins in lytic bacteriophage for subsequent presentation by antigen presenting cells to T helper cells. Disease-associated antigens are provided as are the use of such antigens in vaccines for inducing an immune response and preventing or treating disease. Moreover, the present invention provides antibodies, which specifically bind to MHC class II-dependent disease-associated antigens or epitope peptides thereof, and their diagnostic and therapeutic use. | 2010-04-01 |
| 20100080793 | DcR3 polypeptide, A TNFR homolog - A TNFR homolog, identified as DcR | 2010-04-01 |
| 20100080794 | MUTANT POLYPEPTIDE HAVING EFFECTOR FUNCTION - Mutant polypeptides of the present invention contain an Fc region in which a cysteine residue is substituted for the second amino acid from the glycosylation site to the N terminal side in the Fc region. The Fc region is preferably a human IgG Fc region. The mutant polypeptides of the present invention may also contain an N-linked sugar chain at the glycosylation site in Fc region. Furthermore, a polypeptide domain other than the Fc region of the mutant polypeptides of the present invention may be a polypeptide molecule that recognizes a human cell surface molecule. | 2010-04-01 |
| 20100080795 | BIODEGRADABLE THERMOGELLING POLYMER - There is provided a polymer comprising blocks of at least one polyethylene glycol) block, at least one poly(propylene glycol) block and at least one poly(hydroxybutyrate) block. Also provided is a method of making the polymer and a method of using the polymer. | 2010-04-01 |
| 20100080796 | Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders - The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder. | 2010-04-01 |
| 20100080797 | THERAPY PROCEDURE FOR DRUG DELIVERY FOR TRIGEMINAL PAIN - The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region. | 2010-04-01 |
| 20100080798 | KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM - The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-γ by lymphocytes or other immune cells in a mammal. Inhibition of IFN-γ is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease. | 2010-04-01 |
| 20100080799 | WSTF REGULATES THE DNA DAMAGE RESPONSE OF H2A.X VIA NOVEL TYROSINE KINASE ACTIVITY - The present invention relates to methods of detecting and regulating cellular DNA damage as well as methods of screening compounds suitable for modulating cellular DNA damage. The methods of the present invention utilize antibodies that selectively bind to a phosphorylated tyrosine residue in a SQEY tyrosine phosphorylation motif sequence or a phosphorylated serine residue in a KENSSQ phosphorylation motif sequence, where the phosphorylated serine residue is closest to the glutamine residue. Also encompassed by the present invention are methods of treating a subject having cancer. These methods involve the administration of an agent that modulates the phosphorylation of the tyrosine residue in a SQEY motif. Suitable agents for modulating the phosphorylation of the tyrosine residue of the SQEY motif are also disclosed. | 2010-04-01 |
| 20100080800 | Humanized antibody - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 2010-04-01 |
| 20100080801 | LIR-9, a novel leukocyte immunoglobulin-like receptor - A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridizes to defined nucleotide sequences, processes for producing polypeptides of the LIR family, and specific antibodies directed against LIR polypeptides. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function. | 2010-04-01 |
| 20100080802 | ANTI-IL-TIF ANTIBODIES AND METHODS OF USE - The present invention relates to ZCYTO18 polynucleotide and polypeptide molecules. The ZCYTO18 is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2010-04-01 |
| 20100080803 | LABOR BIOMARKERS, METHODS COMPRISING SAME, AND METHODS TARGETING SAME - The present invention provides methods of predicting or detecting labor in a female subject and methods of testing a compound for an ability to delay the onset of labor. The present invention also provides methods of testing a labor marker useful in the diagnostic methods, isolated peptides identified in the present invention, methods for inhibiting labor, utilizing the peptides, and kits comprising methods of the present invention. | 2010-04-01 |
| 20100080804 | METHODS OF TREATING INFLAMMATORY DISORDERS OF THE LUNGS - 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation. | 2010-04-01 |
| 20100080805 | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof - A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed. | 2010-04-01 |
| 20100080806 | Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same - The present invention discloses a monoclonal antibody against the extracellular domain of human tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 (death receptor 5), The present invention also provides a method of producing the monoclonal antibody, amino acid sequences of the variable regions of the monoclonal antibody's heavy chain and light chain, as well as use of the monoclonal antibody for preparation of a medicament in the treatment of various cancers and/or AIDS. | 2010-04-01 |
| 20100080807 | Methods and Compositions for Treating Viral Hemorrhagic Fever - Disclosed herein are methods and compositions for treating viral hemorrhagic fever in a subject by use of at least one inhibitor or suppressor of oxidase, inducible nitric oxide synthase (iNOS) and apoptosis pathway. | 2010-04-01 |
| 20100080808 | ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE - The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same. | 2010-04-01 |
| 20100080809 | GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF - The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR. | 2010-04-01 |
| 20100080810 | METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES - The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample. | 2010-04-01 |
| 20100080811 | ANTI-MYOSTATIN ANTIBODIES - Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species. | 2010-04-01 |
| 20100080812 | Antibodies against human IL17 and uses thereof - An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between C | 2010-04-01 |
| 20100080813 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection. | 2010-04-01 |
| 20100080814 | NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 2010-04-01 |
| 20100080815 | MN Gene and Protein - A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression. | 2010-04-01 |
| 20100080816 | TOLEROGENIC POPULATIONS OF DENDRITIC CELLS - Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use. | 2010-04-01 |
| 20100080817 | HUMAN PAPILLOMAVIRUS / Ii-KEY HYBRIDS AND METHODS OF USE - The present invention is directed towards compositions comprising Ii-Key/HPV hybrid peptides. The hybrid peptides of the present invention are effective in the generation of CD4+ helper T cell immune responses directed towards the specific HPV epitopes encoded in the hybrid peptide. The inclusion of the Ii-key peptide in the hybrid causes the peptide to have greater immunogenicity as compared to control peptide. The inclusion of Ii-Key/HPV hybrid in a peptide vaccine formulation composing both HPV hybrid and HPV CTL epitope peptide (administered concurrently or sequentially) leads to a greater CTL activity against HPV CTL epitopes. The hybrid peptides of the present invention may be useful, for example, for the immunization of subjects against HPV. | 2010-04-01 |
| 20100080818 | Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response - The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins. | 2010-04-01 |
| 20100080819 | MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1 - Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases. | 2010-04-01 |
| 20100080820 | Preparation of a Therapeutic Composition - Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm. | 2010-04-01 |
| 20100080821 | Energy Compositions - Described herein are caffeine-free compositions that provide a sense of energy and well-being. In one aspect, the compositions include a blend of natural herbs or herbal extracts such as at least one | 2010-04-01 |
| 20100080822 | CINNAMOMI AND PORIA COMPOSITION, METHOD TO PREPARE SAME AND USES THEREOF - This invention provides a method for identifying a composition of Cinnamomi and Poria. This invention further provides a composition comprising: Ramulus Cinnamomi, Poria Cortex, Moutan Radicis, Radix Paeonize Alba, and Semen Persicae. This invention provides various uses of these compositions. | 2010-04-01 |
| 20100080823 | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants - Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same. | 2010-04-01 |
| 20100080824 | HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF - The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences. | 2010-04-01 |
| 20100080825 | FILOVIRUS VECTORS AND NONINFECTIOUS FILOVIRUS-BASED PARTICLES - Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles. | 2010-04-01 |
| 20100080826 | PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS AND NON-VIRAL BASED CANCERS - The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostrate cancer realized immediate beneficial results with no side effects. | 2010-04-01 |
| 20100080827 | RECOMBINANT INFLUENZA VIRUSES EXPRESSING TUMOR-ASSOCIATED ANTIGENS AS ANTITUMOR AGENTS - The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo. | 2010-04-01 |
| 20100080828 | IMMUNOGENIC SEQUENCES - The application relates to nucleic acids which encode enzymes responsible for the production of the O-antigen of | 2010-04-01 |
